SEQUENCES

SEQ ID NO. 1 (AB12 VH):
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRYIINWVRQAPGQGLEWMGRIIPILGVEN
YAQKFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARKDWFDYWGQGTLVTVSSAS
TKGPSVFPLA

SEQ ID NO. 2 (AB12 VL):
EIVLTQSPGTLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYGASSRATGIPD
RFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGGGTKVEIKRTVAAPSVFIFP

SEQ ID NO. 3 (VH CDR1):
RYIIN

SEQ ID NO. 4 (VH CDR2):
RIIPILGVENYAQKFQG

SEQ ID NO. 5 (VH CDR3):
KDWFDY

SEQ ID NO. 6 (VL CDR1):
RASQSVSSYLA

SEQ ID NO. 7 (VL CDR2):
GASSRAT

SEQ ID NO. 8 (VL CDR3):
QQYGSSPLT

Figure 1



sADCx25, 0.1 mg/kg, day 1
Tumour Volume mm3
4000
3000
2000
1000
0
0
20
40
60
Days
sADCx25, 0.5 mg/kg, day 1
Tumour Volume mm3
4000
3000
2000
1000
0
0
20
40
60
Days
sADCx25, 1 mg/kg, day 1
Tumour Volume mm3
3000
2000
1000
0
0
20
40
60
Days

Figure 2A



Gemcitabine + sADCx25, 0.1 mg/kg, day 5
Tumour Volume mm3
4000
3000
2000
1000
0
0
20
40
60
Days
Gemcitabine + sADCx25, 0.5 mg/kg, day 5
Tumour Volume mm3
5000
4000
3000
2000
1000
0
0
20
40
60
Days
Gemcitabine + sADCx25, 1 mg/kg, day 5
Tumour Volume mm3
5000
4000
3000
2000
1000
0
0
20
40
60
Days

Figure 2B



Vehicle
Tumour Volume mm3
4000
3000
2000
1000
0
0
20
40
60
Days
Gemcitabine only (80mg/kg, q3dx4)
Tumour Volume mm3
4000
3000
2000
1000
0
0
20
40
60
Days

Figure 2C